ortho clinical diagnostics
glassdoor has 161 ortho clinical diagnostics reviews submitted anonymously by ortho clinical diagnostics employees. read employee reviews and ratings on glassdoor to decide if ortho clinical diagnostics is right for you .
ortho clinical diagnostics is a proud supporter of the advamed code of ethics on interactions with healthcare professionals .
ortho clinical diagnostics today announced the appointments of accomplished industry veterans as independent members of the board of directors of the company’s parent, ortho - clinical bermuda co. ltd .
interview candidates at ortho clinical diagnostics rate the interview process an overall positive experience. interview candidates say the interview experience difficulty for ortho clinical diagnostics is average. some recently asked ortho clinical diagnostics interview questions were ,
which kind of management style do you like ?
and
conversational .
. 50% of the interview applicants applied online .
i applied through college or university. i interviewed at ortho clinical diagnostics (rochester, ny) in january 2013 .
ortho clinical diagnostics is formed from the merger of two johnson & johnson companies: ortho diagnostic systems, a worldwide leader in transfusion medicine reagents and instrument systems, and johnson & johnson clinical diagnostics (formerly a division of eastman kodak co .), a worldwide leader in clinical laboratory systems
i applied online. the process took 2 weeks. i interviewed at ortho clinical diagnostics (new york, ny) .
i applied online. the process took 2 weeks. i interviewed at ortho clinical diagnostics (rochester, ny) in april 2016 .
i applied online. the process took 3 + months. i interviewed at ortho clinical diagnostics (rochester, ny) in may 2015 .
i applied online. the process took 3 + months. i interviewed at ortho clinical diagnostics (raritan, nj) in may 2016 .
i applied through an employee referral. the process took a week. i interviewed at ortho clinical diagnostics (rochester, ny) in october 2016 .
i applied through college or university. the process took 3 weeks. i interviewed at ortho clinical diagnostics (ewing, nj) in december 2015 .
i applied through a recruiter. the process took a week. i interviewed at ortho clinical diagnostics (san francisco, ca) in october 2017 .
i applied in - person. the process took 2 weeks. i interviewed at ortho clinical diagnostics (new brunswick, nj) in january 2011 .
© ortho clinical diagnostics 2018. this site is published by ortho clinical diagnostics, which is solely responsible for its contents. product availability is subject to fulfillment of regulatory requirements in each market. this site was written for healthcare professionals in india only. last modified date: 24 - 08 - 2017 01: 45
© ortho clinical diagnostics 2018. this site is published by ortho clinical diagnostics, which is solely responsible for its contents. product availability is subject to fulfillment of regulatory requirements in each market. this site was written for healthcare professionals in united kingdom only. last modified date: 02 - 09 - 2015 07: 27
© ortho clinical diagnostics 2018. this site is published by ortho clinical diagnostics, which is solely responsible for its contents. product availability is subject to fulfillment of regulatory requirements in each market. this site was written for healthcare professionals in the canada only. last modified date: 01 - 09 - 2015 09: 02
i applied through college or university. the process took 6 + weeks. i interviewed at ortho clinical diagnostics (north charleston, sc) in february 2011 .
© ortho clinical diagnostics 2018. this site is published by ortho clinical diagnostics, which is solely responsible for its contents. product availability is subject to fulfillment of regulatory requirements in each market. this site was written for healthcare professionals in the united states only. last modified date: 15 - 05 - 2015 03: 00
ortho clinical diagnostics today announced that terre haute regional hospital is the first u. s. medical center to install the ortho vision tm analyzer, a highly interactive, fully automated analyzer for transfusion medicine laboratories .
for more than 75 years, ortho clinical diagnostics has been guided by its purpose: to improve and save lives with diagnostics. review our timeline to discover important moments throughout our rich history of pioneering life - impacting advances .
“we are pleased to welcome carl, ron, tom and joe, who each brings the wealth of related industry experience needed to help us revitalize ortho clinical diagnostics as a premier in vitro diagnostics company, ” said martin d. madaus, chairman and chief executive officer of ortho clinical diagnostics. “their deep expertise across clinical laboratories and transfusion medicine will provide valuable insights as we look to transform our company and enhance our focus on our customers. ”
download technical documents, including instructions for use, material safety data sheets, specifications, control assay sheets, maintenance logs, and more for ortho clinical diagnostics products .
ortho clinical diagnostics receives 510 (k) clearance for ortho vision™ analyzer, making it commercially available in the united states. ortho vision™ analyzer automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing the lab' s reliance on manual methods
“the lab at terre haute regional hospital is the perfect setting to demonstrate everything the ortho vision tm analyzer can do to enhance blood - bank efficiency, ” said heidi casaletto, head of transfusion medicine at ortho clinical diagnostics .
through ortho clinical diagnostics’ proprietary intellicheck® technology, the ortho vision tm analyzer verifies and documents diagnostic checks throughout the testing process, while e - connectivity® technology provides 24 / 7 remote data tracking that monitors instrument performance while maximizing uptime .
about ortho - clinical diagnostics, inc. ortho - clinical diagnostics, inc. delivers the high - quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. the company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. ortho - clinical diagnostics also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. for more information, visit urltoken
martin madaus, ortho clinical diagnostics chairman & ceo, discusses how the diagnostics company has performed after the carve - out with help from the carlyle group as well as the state of the blood testing industry. the carlyle group co - ceo david rubenstein also weighs in .
for use with ortho’s vitros® chemistry, immunodiagnostics and integrated systems, allowing u. s. clinical laboratories to improve results throughout diagnostic testing
ortho clinical diagnostics delivers high - quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. the company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. ortho clinical diagnostics also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. for more information, visit urltoken .
ortho products develops the first blood bank anti - d test for the clinical market. this is a revolutionary advance in the burgeoning blood banking industry .
) - - ortho clinical diagnostics today announced the appointments of accomplished industry veterans carl hull, ron labrum, thomas mac mahon and josé (joe) e. almeida as independent members of the board of directors of the company’s parent, ortho - clinical bermuda co. ltd. ocd became a stand - alone company in july 2014. these appointments bring the total number of directors to ten .
new brunswick, nj, january 16, 2014 - - johnson & johnson (nyse: jnj) today announced that it has received a binding offer from the carlyle group to acquire its ortho - clinical diagnostics business for $ 4. 15 billion .
ortho clinical diagnostics, a 2014 acquisition from johnson & johnson, is a leading global provider of in vitro diagnostics, and is a trusted partner and adviser of hospitals, hospital networks, blood banks and labs around the world. the longstanding responsible business priorities and practices that define the company are embedded in a sustainable operations framework. this framework enables ortho to help protect the planet by making conscientious choices and implementing effective environmental programs .
when we came in, in 2014, we focused the business on the core businesses for clinical labs and immunohematology, and worked on making the very comprehensive portfolio of more competitive products and also focusing on clinical diagnostics as an independent company and really bringing our customer service or our customer support scores to higher class level again .
a: ortho has been a global leader in in vitro diagnostics for many, many years. almost 70 years or more. it is really number one in the field of immunohematology worldwide, but also in a significant position in clinical labs worldwide. that' s the main reason why the company was acquired by carlyle .
to get there, ortho is focused on delivering reliable and innovative products to hospital labs via a pair of businesses: its immunohematology blood - typing business and its core clinical laboratory business. madaus isn' t particularly concerned that the emergence of point - of - care and remote products and services at all threatens the long - term future of the centralized hospital diagnostics lab .
“ortho - clinical diagnostics plays an important role in healthcare, and we’re confident that it’s well positioned to serve the interests of its patients, customers, and employees, ” said alex gorsky, chairman and chief executive officer of johnson & johnson. “this transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for johnson & johnson. ”
ortho products, inc. , is formed in linden, new jersey, as a division of johnson & johnson
for clinical purposes, no single laboratory test is adequately sensitive and specific to diagnose chagas disease. diagnosis generally is made by using at least two different serologic tests (e. g. , diagnostic elisa tests, immunofluorescence assay, or indirect hemagglutination) (1) and by considering clinical findings and exposure risk. clinical diagnostic testing for chagas disease is available through commercial laboratories and the division of parasitic diseases (dpd) at cdc. after diagnosis, health - care providers should conduct a thorough clinical evaluation to determine the stage of disease, develop an appropriate treatment plan, and provide information regarding prognosis. cdc is preparing guidance for the clinical evaluation, staging, management, and treatment of patients with chagas disease .
third, i would say, is companies are looking for a good fit in terms of strategic fit, or companies are looking for getting into in vitro diagnostics that have maybe small or no footprint. they see this as a scale play from the few ways to actually get into in vitro diagnostics .
the biggest med tech pe buyout of 2014, by far, was the more than $ 4 billion purchase of johnson & johnson ($ jnj) unit ortho clinical diagnostics by the carlyle group ($ cg). now, roughly two years after the deal was originally announced, ortho wants to assure wall street that it' s on the right track. that' s especially important after reports earlier this year questioned whether the buyout lenders were on board with the company' s earnings, which of course are no longer publicly reported .
carl hull is the former chairman and chief executive officer of gen - probe, a molecular diagnostics company. he is a 30 - plus year veteran of the diagnostics and life sciences industries. previously, mr. hull held executive positions at applied biosystems, applied imaging, ventana medical systems and abbott diagnostics. he served as the chairman of the board of the california healthcare institute from 2010 to 2012 and previously served on the board of directors of advameddx, an industry advocacy organization .
a version of the ortho vision tm analyzer is also available in europe, japan, latin america, canada and australia .
food and drug administration. product approval information licensing action. ortho t. cruzi elisa test system. available at urltoken .
martin madaus, who was a senior healthcare adviser to carlyle, took over ortho when the deal closed at the end of june 2014. he was previously chairman, president and ceo of millipore ($ mil) and, before that, president and ceo of roche diagnostics north america .
energy management. ortho has implemented a number of energy efficiency improvements that have resulted in reduced consumption of carbon - intensive fuels .
in 2005, a new commercial test for blood - donation screening for chagas disease was developed. the test, manufactured by ortho - clinical diagnostics (raritan, new jersey), is an enzyme - linked immunosorbent assay (elisa) that uses epimastigote lysate antigens for detection of antibodies to t. cruzi in serum and plasma (8). in clinical trials evaluating the test, including the american red cross study, blood donor specimens with initially reactive results were retested twice and considered repeat reactive if one or both of the repeat tests were reactive. repeat reactive specimens from the clinical trials underwent further testing using a radioimmunoprecipitation assay (ripa); those with positive ripa results were considered confirmed positive. however, fda has not licensed a supplemental test as a confirmatory assay in blood donation screening for t. cruzi antibodies .
a: ortho will be a stronger and more competitive stand - alone company very much focused on delivering value to our core customers which are the hospital customers. we' ll stay in in vitro diagnostics, largely hospital - oriented organizations. we' ll probably be much bigger in asia, particularly in china .
composting and recycling. ortho’s sustainability initiatives have resulted in a 25% increase in composting rates and a 10% increase in recycling rates in 2016 .
he told fiercemedicaldevices in the interview featured below that ortho has been actively investing in building out as a standalone company, which has dragged on earnings in the near term. but he added that ortho has returned to revenue growth - - and is aiming to get to about a 4% run rate .
ortho seeks ways to reduce its environmental footprint by designing technology and systems with the highest operational efficiency and therefore the lowest impact on the earth and its resources. in support of that mission, in 2016, ortho set new goals to be met by 2018 that build on its impressive record of environmental stewardship. they include :
we have recently introduced in immunohematology the ortho vision platform, which is a generation of automated analyzers, a game changer in immunohematology. we have also a strong pipeline to expand on that launch with multiple additions. in clinical labs, we have also built now a strong pipeline of future instruments and menus that will actually be starting this year and then in 2017 and 2018 .
a: yeah, all of the above. i would say it' s early. a company like this definitely has a lot of interested parties, as we know from the past. there are very few scale companies in in vitro diagnostics available. obviously, this is an attractive target. ortho is large enough to do an ipo, so both are possible in the future .
designed with secure monitoring technologies for safety checks and balances, the ortho vision tm analyzer gives transfusion medicine professionals the ability to track critical steps in the immunohematology testing process .
on december 13, 2006, based in part on preliminary results from the american red cross study, fda licensed the ortho t. cruzi elisa test system to screen blood donors in the united states. the new assay also is labeled for testing plasma and serum samples from living cell and tissue donors and from heart - beating organ donors, but is not labeled for general clinical diagnostic use .
ortho has been relatively quiet on the dealmaking front in the past few years with only two smallish deals: one with quotient in immunohematology and the other with astute medical for its acute kidney injury biomarker test. madaus said these deals are emblematic of what ortho is looking for since one is for new content that it can run on its machines, while the other is for a new platform technology .
raritan, new jersey. ortho generated 11 mwh of clean energy in 2016 using onsite solar panels. that amount represents 12% of the site’s energy demand and enough energy to power 11, 000 average homes for one year. the continuation of the successful “after - hours lights - out” program, introduced in 2015 at ortho’s locations in raritan and pompano beach, resulted in a co 2 emissions avoidance of 94, 000 pounds in 2016 .
reduction of hazardous or non - hazardous waste. in 2016, at its raritan, new jersey, and rochester sites, ortho shifted an additional 70 tons of medical waste stream to a mixed - waste recovery plant for reuse. another example is in pompano beach, florida, where ortho completed a sustainability project in 2016 that led to recycling a waste stream previously managed as medical waste. this resulted in a decrease of 16% of medical waste .
rochester. working with ironclad energy—which completed the acquisition of a nearby power plant that supplies all utilities to key ortho manufacturing operations—will yield reductions in the plant’s co 2 emissions by 2018 by converting the coal - powered plant to natural gas .
a: we certainly have a new spirit and energy when you compare ortho as a division of j & j. we' re independent. people are generally excited about the fact that they can take this business to become an independent stand - alone company. we have, in the last year and a half, added a little bit over 1000 new employees around the world. that' s a testimony to the fact that we are a good story and people want to join us. they like our purpose, our mission, to save lives through diagnostics .
zero landfill. in pencoed, uk, ortho reduced hazardous waste by 39% from 2011 through 2016. by implementing strict recycling processes, the facility had no waste going to landfills throughout 2016, which led the site to achieve zero landfill status .
financially challenged by current owner (the carlyle group). some benefits being cut. company announced that ortho' s retirement plan will be discontinued at the start of 2019. health care contribution for employee is good but is being reduced for dependents (spouse and children). ortho offers a company bonus based on performance but rumors of that plan facing restructuring. bureaucracy abounds, especially in the company' s quality organization. hard to get work done so being persistent is a necessity. understaffed in operations areas. pay is being restrained to help meet net earnings goals .
screening blood donations for t. cruzi antibodies can identify persons with previously undiagnosed chagas disease and further enhance the safety of the u. s. blood supply. however, as with any screening test, limitations exist. although available data regarding the performance of the new assay have suggested high sensitivity and specificity (8, 9), some false - negative results have occurred with this assay (8) and with other assays used to screen for t. cruzi antibodies (10). in addition, when a screening assay is used in a population with low disease prevalence, a greater proportion of false - positive results can be expected. donors with reactive screening assay results require further clinical diagnostic testing to verify t. cruzi infection and to guide clinical management .
conserving water. in ortho’s global center of excellence for r & d in rochester, new york, the company’s water - use reduction program lowered consumption by 21 million gallons per year in 2014 and 2015. in early 2016, new water pumps were installed, resulting in projected savings of 10 million to 12 million gallons per year .
“with surgeons waiting to operate at a moment’s notice, the ortho vision tm analyzer will enable our blood bank to work more quickly and efficiently, providing the people of our region the best care available. we won’t waste precious time – sometimes those minutes are the difference between life and death – flying patients over our hospital to a different city. ”
the other one is a content link in clinical labs with astute medical, which has developed a very innovative marker for acute kidney injury which is a very big problem for our hospital customers. these two are basically pretty typical for what we' re looking for. one is new content, a new valuable medical content that we can put on one of our machines. the other one is a new platform technology that would be something completely new .
dr. philip levine, a pioneer in the field of hematology, joins ortho products to continue his breakthrough research into the mechanics of the rh system in human blood. this marks the beginning of the company' s commitment to diagnostic medicine. among dr. levine' s many contributions is research that leads to the development of rh immune globulin to protect rh - negative women against isoimmunization, saving the lives of thousands of babies .
general recruiter contacted me excited about proposing a sales position to me. then he referred me to ortho' s recruiter, and she called and spent an hour speaking to me. then there was a phone interview with the hiring manager, and then an in - person interview with hiring manager. he was still interviewing other candidates. he said he will let me know in a day or two as he had no time to wait and wanted to make final decision soon. after 4 days i did not hear any thing from him. i contacted the other recruiter and she did not respond after couple of days. then i contacted the general recruiter and he said they were moving with another candidate and he was going to give me feedback (which i really cared about and was curious). i gave him my availability and he never contacted me. they completely dropped the ball and neither of them had given me any feedback after the interview! i felt disregarded as a candidate and was disappointed with ortho. advice to management is also that if you do not treat candidates right, it will ruin your own reputation right there and then too !
after a clinical trial in 2005 with approximately 40, 000 blood donors resulted in only one repeat reactive specimen (which tested negative with ripa) (8), the american red cross conducted a larger study of the new screening assay in areas where chagas was expected to be more prevalent. the study was conducted in three collection facilities of the american red cross, including the southern california region (los angeles, california), the northern california region (oakland, california), and the arizona region (tucson, arizona). blood donations collected during august 28, 2006 - - january 28, 2007, were tested with the screening assay for those blood donors willing to participate in the study. all donors were asked to participate; 78. 5% agreed, and their specimens were tested .
- extremely difficult to get hired as a full - time employee despite promises from senior management - slow processes / change / updates - this is a company set in old ways. any simple change to a document is a process that usually takes 3 + weeks with extensive oversight and approvals. don' t expect to bring any new ideas to the table and have them considered realistic. the amount of capital and energy required to update processes / workflow / implement new ideas is ridiculous. - morale: no more company picnics, or holiday parties. ortho is now owned by a private equity company, so expect all belts to tighten. the employee morale is at an all - time low. - older generation folks tend to be resistant to any change, expect to put up a fight with any new projects you start .
chagas disease, a zoonotic disease caused by the bloodborne parasite trypanosoma cruzi, affects an estimated 11 million persons throughout much of latin america. in endemic areas, t. cruzi is transmitted primarily by triatomine insects (i. e. , kissing bugs); infection also can occur via blood transfusion, congenital transmission, organ transplantation, laboratory incident, and ingestion of triatomine - contaminated food or drink (1). to evaluate an investigational assay for detecting t. cruzi infection in blood donations, the american red cross conducted a clinical trial during august 2006 - - january 2007, screening 148, 969 blood samples at three blood - collection centers in the united states. in january 2007, after the new assay was licensed by the food and drug administration (fda), other centers began screening donors for t. cruzi. this report describes the results of the american red cross study, which identified 32 donations (approximately one in 4, 655) as confirmed positive for t. cruzi antibodies. as blood - donation screening for chagas disease becomes more widespread, public health officials and health - care providers should anticipate increased numbers of questions regarding the diagnosis, evaluation, and management of chagas disease .
terre haute regional hospital, based in terre haute, indiana, is in the process of becoming a level ii trauma center, allowing patients with acute emergency needs to be treated within their community rather than traveling much farther away .
laboratory personnel can also log on anytime, anywhere to collaborate on interpreting results in real time for an extra level of confidence .
“switching from manual to fully automated will enable the specialists in the lab to focus on getting the blood products ready for the patient while the instrument runs the type and screen tests for them. the lab can now do its job as the backbone of the trauma center. ”
a hospital er charges an ‘after - hours’ fee. who has to pay it ?
the opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of news - medical. net .
at st. john' s, we are building an innovation center in pharmaceutical technology. we are involved with double upping new drug delivery systems, as well as a new processing agreement. in addition, we are focussing on personalized medications .
with the advent of artificial intelligence, it is imperative that we examine the ethics of machine learning and data collection. hugh whittall, director of the nuffield council on bioethics, explains what ai is, how it is transforming the healthcare industry and the ethical concerns of the council .
dr. jagadeesh bayry from inserm discusses his recent research in the field of immunology, and how t regulatory cells activate, rather than suppress, basophils .
news - medical. net provides this medical information service in accordance with these terms and conditions. please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician / doctor and the medical advice they may provide .
this site complies with the honcode standard for trustworthy health information: verify here .
by continuing to browse or by clicking
accept all cookies ,
you agree to the storing of first and third - party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. find out more .
enclose phrases in quotes. use a + to require a term in results and - to exclude terms. example: + water - europe
private equity loves a good med tech story. there are seemingly endless opportunities for financial engineering - - rolling up companies or trimming them down with a restructuring. and, unlike their typical biotech peers, med tech companies often have revenues - - even if they aren' t growing very fast, or at all .
a: we' re aiming to roll at market rates, or in some segments slightly above. in our industry, in these segments, the market rate will likely be around 4% . i think at that level, again, varying by geography, we' d be comfortable .
a: building a standalone capability, that means standalone financial systems, independent distribution, and being a fully integrated standalone company is the prerequisite. that' s what we' re working on today. that' s one of our top three priorities. that should be completed by the end of this year .
second, a company needs to grow. you don' t have to grow like a startup, but you have to show that you have a strong position in the market and that customers like your services, your product. sales growth is a good sign that that' s happening again .
q: you mentioned the split from j & j. how do you see the culture of the company as changing, if at all, since that split ?
a: we' ve made two deals in the last year and a half. one is around a new platform technology with quotient in this space of immunohematology for a very specialized field for typing of many, many, different blood types and antibodies, antigens, in one sample .
q: the bloomberg stories and the moody' s downgrade from earlier this year reflected some concerns on the earnings front. can you give me a sense of how you might respond to those concerns ?
a: since we' ve become an independent company we reinvested in the new capabilities to grow the company. we' re really working on building these back - office systems that are so critical to become a stand - alone company. that' s also an investment. these are large multi - year efforts that are starting to show results now .
we know that we' re acquiring revenues again; that is evident in our full year of 2015 results .
a: hospitals have to adjust to the new payment environment. they' re dealing with too much hospital bed capacity on the one hand [ and ] on the other hand, increasing demand for their services. hospitals are trying to push more of their care as possible to push out into lower - cost environments, out more into ambulatory care or into physician offices .
that creates a different type of customer that wants to look to companies for solutions across different points in the network and helps them to standardize a little bit more. the hospital lab, even though it may be reconsidered, is there to stay. i' m really convinced about that. you do provide an essential service to so many, almost all, healthcare decisions .
© 2018 questex llc. all rights reserved. 275 grove street, suite 2 - 130 newton, ma 02466
persons using assistive technology might not be able to fully access information in this file. for assistance, please send e - mail to: mmwrq @ urltoken. type 508 accommodation and the title of the report in the subject line of e - mail .
chagas disease has an acute stage, typically asymptomatic or with mild symptoms (e. g. , fever, malaise, swelling at the site of innoculation and lymphadenopathy) during the first 6 - - 8 weeks after infection. if not treated, infection is lifelong with low - level, intermittent parasitemia. the majority of infected persons remain asymptomatic in the chronic indeterminate phase (i. e. , a prolonged period of clinically silent infection that follows acute primary infection). however, an estimated 30% will have onset of chronic symptomatic disease, usually decades after the initial infection, with cardiac manifestations (e. g. , cardiomyopathy, arrhythmias, and sudden death) or gastrointestinal involvement (e. g. , megaesophagus or megacolon) .
in the united states, vector - borne transmission of chagas disease is rare (2). however, one study revealed an increasing chagas seroprevalence among blood donors in los angeles county, california, from 1996 (one in 9, 850 donors) to 1998 (one in 5, 400 donors) (7). in 1991, a questionnaire was introduced to screen blood donors; those reporting a history of chagas disease are deferred, but most persons with chagas disease likely are unaware of their infections. seven cases of transfusion - associated transmission have been documented in the united states and canada during the past 20 years; all occurred in immunosuppressed recipients (3 - - 6). because acute infections often are asymptomatic and the level of awareness of chagas disease among clinicians is low, cases of transfusion - associated transmission can go undetected .
a total of 148, 969 blood - donation specimens were tested; 63 specimens from 61 donors were repeat reactive for t. cruzi antibodies (approximately one in 2, 365 donations). among the 61 donors with repeat reactive speciments, 40 (66 %) were male; the age range was 17 - - 84 years, with a mean age of 47 years and a median of 50 years. of the 63 repeat reactive specimens, 50 (79% ; one in 1, 993 donations) were collected from the los angeles center, nine (14% ; one in 3, 258 donations) were collected from the oakland center, and four (6% ; one in 5, 995 donations) were collected from the tucson center. fifty - five (90 %) of the 61 donors were allogeneic donors; the remaining six included five autologous donors (two with two reactive donations each) and one directed donor. of the 55 allogeneic donors, 18 (33 %) were first - time donors, and 37 (67 %) had donated blood previously. all of the 63 repeat reactive donations were tested with ripa, of which 32 (51 %) were positive and 31 (49 %) were negative .
sl stramer, phd, american red cross, gaithersburg; ry dodd, phd, da leiby, phd, american red cross, rockville, maryland. rm herron, md, american red cross, los angeles; l mascola, md, los angeles county dept of public health; lj rosenberg, md, california state health dept. s caglioti, blood systems laboratories, tempe; e lawaczeck, dvm, rh sunenshine, md, arizona dept of health svcs. mj kuehnert, md, div of health care quality promotion, national center for preparedness, detection, and control of infectious diseases (proposed); s montgomery, dvm, c bern, md, a moore, md, b herwaldt, md, div of parasitic diseases, national center for zoonotic, vector - borne, and enteric diseases (proposed); h kun, phd, jr verani, md, eis officers, cdc .
findings from the american red cross study described in this report provided evidence to support fda approval of the first blood donor screening test for chagas disease in the united states. use of this test by blood centers to screen for t. cruzi antibodies is not required. however, both the american red cross and blood systems, inc. , blood - collection organizations that are responsible for approximately 65% of the u. s. blood supply, began screening all donations for t. cruzi on january 29, 2007, and providing testing services for smaller blood - collection centers and hospitals that requested testing. fda is expected to recommend implementation of the test by all blood - collection establishments .
the aabb (formerly known as the american association of blood banks) has issued recommendations to its member facilities regarding how to use the new test. * aabb recommends that all components from blood donations that are repeat reactive by the elisa test should be quarantined and removed from distribution, and the donor should be deferred from making donations indefinitely. recipient tracing should be conducted to identify and test recipients of blood components collected previously from donors who are confirmed positive (i. e. , repeat reactive by elisa and positive by ripa). aabb also suggests testing at - risk family members of donors who are confirmed positive or family members with a similar history of exposure to vectors in an endemic area (e. g. , the children of seropositive women). deferred donors, at - risk family members, and potentially infected recipients should be referred to health - care providers for evaluation and management .
cases of chagas disease likely will be increasingly identified as a result of screening blood donors for infection with t. cruzi. in addition, requests for diagnostic testing might become more frequent as awareness of chagas disease increases among clinicians and the general public. most identified cases likely will represent chronic infections that were acquired years earlier .
chagas treatment options are limited and are most effective during the acute stage of infection. however, increasing evidence suggests that treatment of persons with chronic infections can result in seroreversion and prevent progression of cardiac morbidity (1). treatment of women of childbearing age with chagas disease can decrease the risk for congenital transmission. antitrypanosomal medication in the united states is currently available only through cdc under an investigational new drug protocol .
questions regarding laboratory diagnosis, evaluation, and management of chagas disease can be posed to dpd by telephone, 770 - 488 - 7775. additional information regarding chagas disease is available at
who expert committee. control of chagas disease. world health organ tech rep ser 2002; 905: i - - vi, 1 - - 109 .
herwaldt bl, grijalva mj, newsome al, et al. use of polymerase chain reaction to diagnose the fifth reported us case of autochthonous transmission of trypanosoma cruzi, in tennessee, 1998. j infect dis 2000; 181: 395 - - 9 .
cimo pl, luper we, scouros ma. transfusion - associated chagas' disease in texas: report of a case. tex med 1993; 89: 48 - - 50 .
lane dj, sher g, ward b, ndao m, leiby d, hewlett b. investigation of the second case of transfusion transmitted chagas disease in canada. presented at: 42nd annual meeting of the american society of hematology, san francisco, california; december 1 - - 5, 2000 .
leiby da, lenes ba, tibbals ma, tames - olmedo mt. prospective evaluation of a patient with trypanosoma cruzi infection transmitted by transfusion. n engl j med 1999; 341: 1237 - - 9 .
saulnier sholler gl, kalkunte s, greenlaw c, mccarten k, forman e. antitumor activity of nifurtimox observed in a patient with neuroblastoma. j pediatr hematol oncol 2006; 28: 693 - - 5 .
leiby da, herron rm jr, read ej, lenes ba, stumpf rj. trypanosoma cruzi in los angeles and miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. transfusion 2002; 42: 549 - - 55 .
tobler lh, contestable p, pitina l, et al. evaluation of a new enzyme - linked immunosorbent assay for detection of chagas antibody in us blood donors. transfusion 2007; 47: 90 - - 6 .
leiby da, wendel s, takaoka dt, fachini rm, oliveira lc, tibbals ma. serologic testing for trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme - linked immunosorbent assay kits. j clin microbiol 2000; 38: 639 - - 42 .
use of trade names and commercial sources is for identification only and does not imply endorsement by the u. s. department of health and human services. references to non - cdc sites on the internet are provided as a service to mmwr readers and do not constitute or imply endorsement of these organizations or their programs by cdc or the u. s. department of health and human services. cdc is not responsible for the content of pages found at these sites. url addresses listed in mmwr were current as of the date of publication .
disclaimer all mmwr html versions of articles are electronic conversions from ascii text into html. this conversion may have resulted in character translation or format errors in the html version. users should not rely on this html document, but are referred to the electronic pdf version and / or the original mmwr paper copy for the official text, figures, and tables. an original paper copy of this issue can be obtained from the superintendent of documents, u. s. government printing office (gpo), washington, dc 20402 - 9371; telephone: (202) 512 - 1800. contact gpo for current prices .
morbidity and mortality weekly report centers for disease control and prevention 1600 clifton rd, mailstop e - 90, atlanta, ga 30333, u. s. a
cookies are being used on this website to improve your user experience. you have the option to change your cookie settings at any time. please read our privacy policy to learn more .
please select a location and language. your preference will be saved for future visits to this site. you may change your location at any time by clicking “change location” in the navigation .
ron labrum most recently served as president and chief executive officer of fenwal, a global leader in transfusion technology. his prior role was as chairman and chief executive officer of cardinal health’s healthcare supply chain services segment. mr. labrum has more than 30 years of experience in the medical device and distribution industry, serving in senior leadership roles with fortune 100 companies including allegiance corporation, baxter international and american hospital supply corporation. he currently serves as chairman of the board of suture express and he is a director of wright medical group and great basin scientific .
thomas mac mahon currently serves as an executive partner at foundation medical partners, a healthcare - focused venture capital fund. he is the former chairman and chief executive officer of laboratory corporation of america, one of the largest u. s. medical testing companies. mr. mac mahon began his career with roche laboratories, eventually becoming responsible for all u. s. diagnostic operations of roche. he currently serves as the lead outside director for express scripts, inc. , and is also a director of synapdx corporation and pharmerica corporation, among others .
josé (joe) e. almeida is chairman, president and chief executive officer of covidien plc. he has served as chairman of covidien’s board of directors since march 2012 and as president, chief executive officer and a director of covidien since 2011. prior to being appointed to his current position, mr. almeida was president of the medical devices organization at covidien, where he oversaw several businesses. mr. almeida has held leadership positions at covidien, greatbatch technologies, inc. , american home products’ acufex microsurgical division and johnson & johnson’s professional products division, and began his career as a management consultant at andersen consulting (accenture). he currently serves as chairman of the advanced medical technology association (advamed) board of directors and is on the board of directors of state street corporation and partners in health .
this site uses cookies. by continuing to browse this business wire site (and / or any other business wire website), you accept the use of cookies .
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
please register to access this feature or log in if you are a subscriber, or if you have already registered .
please click the following link to register and submit an upgrade request, so that a member of our sales team can contact you to discuss your requirements .
please click the' request upgrade' button to log your details so that a member of our sales team can contact you to discuss your additional requirements .
you have already logged a callback request. a member of our team will contact you to discuss your access level .
we will try and call you again shortly but in the meantime please check that your contact details are correct and up to date or if you prefer please contact us .
ep vantage brings a fresh view on pharma and biotech with incisive daily analysis, powered by evaluate ltd .
although the site contains up to date data, some features are unfortunately not available on the secondary server. we apologise for any inconvenience this may cause .
alternatively, if you are experiencing problems with an existing order a member of our support team will be happy to assist you. call
please register your details with us to complete your purchase or click login if you have already registered with us .
this report has already been purchased and is available to view now or you may purchase the report again for the latest data .
you have already purchased this report but a problem is preventing you from accessing the information it contains. before calling a member of our support team, please attempt to regenerate your report again from your
you have succeeded in buying the report (s), however you haven' t generated your report (s) yet. please go to purchase history to generate your ordered report (s) now .
the website will be unavailable on thursday 25 april from 12: 00pm for routine maintenance .
this may be the case if you are an existing user and haven' t got a valid email address assigned to your account. if this is the case you will need to login by supplying your subscription id as you would have done previously .
your browser will need to be configured to accept cookies. please contact your it administrator if you are unsure of how to achieve this .
our commitment to you goes far beyond our products. our consultative approach to laboratory management starts the day you become a customer—and continues throughout our business relationship .
glassdoor will not work properly unless browser cookie support is enabled. learn how to enable cookies .
your trust is our top concern, so companies can' t alter or remove reviews .
such a great environment. great people who are really dedicated to the work that is being done here .
working towards building their development opportunities but not there just yet. very promising though .
there is not 1 pro that comes to mind, unless mandatory overtime and horrible raises is considered .
ocd rochester has taken a turn for the better in my opinion .
under new management where they hold the bosses accountable for feeding into the workers. by means of quarterly goal setting, each year your progress is tracked to ensure that the employees that want to progress move !
some old kodak ways still linger but largely have been starved out for the better .
keep up the good work. i like the direction the company is headed .
massive turnover / retirement of highly skilled employees following divestiture. company is good at hiring, horrible and training and succession planning. r & d is clueless, doesn' t work as a team, and constantly complains and points the finger. project management can' t even manage their own group no less manage a team though complicated product development efforts .
currently suck in limbo, not wanting to invest in outdated systems and archaic processes that won' t increase the immediate bottom line but would make massive improvements in long term success. replace the business field leaders, project leaders, product managers, project managers (and whatever other leaders you can add into the management structure) with employees that know what goes into developing and making good quality products .
some of the senior managers at raritan, rochester location work as they are the owners of the company, hr do not listen to new employees. new employees feels they are on their own, many people left due to lack of support from higher management. it is the worst organization to work for, even they don' t keep their words, think 10 times before you apply for any job postings
ortho clinical diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing . ortho serves two primary industries in the medical field : clinical laboratories , by producing platforms and assays that test for a variety of diseases , conditions , and substances ; and immunohematology , by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood . johnson and johnson acquired eastman kodak 's clinical diagnostics division in 1994 ( to form johnson & johnson clinical diagnostics ) , which was then merged with ortho diagnostic systems in 1997 . ortho 's global corporate offices are in raritan , new jersey , while their global research and development center is in rochester , new york . in 2014 , the carlyle group purchased the company from johnson & johnson for $ 4.15 billion . ortho clinical diagnostics now operates as an independent company . ortho clinical diagnostics ( ortho ) unveiled its newly expanded executive leadership team following the acquisition of the company by the carlyle group from johnson & johnson . in his first act as ortho 's chairman and ceo , dr. martin d. madaus announced key appointments in finance , operations , legal and commercial to advance strategic sectors of the in vitro diagnostics ( ivd ) business . 
ortho clinical diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing. ortho serves two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood. johnson and johnson acquired eastman kodak's clinical diagnostics division in 1994 (to form johnson & johnson clinical diagnostics), which was then merged with ortho diagnostic systems in 1997. ortho's global corporate offices are in raritan, new jersey, while their global research and development center is in rochester, new york. in 2014, the carlyle group purchased the company from johnson & johnson for $ 4.15 billion. ortho clinical diagnostics now operates as an independent company. ortho clinical diagnostics (ortho) unveiled its newly expanded executive leadership team following the acquisition of the company by the carlyle group from johnson & johnson. in his first act as ortho's chairman and ceo, dr. martin d. madaus announced key appointments in finance, operations, legal and commercial to advance strategic sectors of the in vitro diagnostics (ivd) business.
ortho clinical diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing. ortho serves two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood. johnson and johnson acquired eastman kodak's clinical diagnostics division in 1994 (to form johnson & johnson clinical diagnostics), which was then merged with ortho diagnostic systems in 1997. ortho's global corporate offices are in raritan, new jersey, while their global research and development center is in rochester, new york. in 2014, the carlyle group purchased the company from johnson & johnson for $ 4.15 billion. ortho clinical diagnostics now operates as an independent company. ortho clinical diagnostics (ortho) unveiled its newly expanded executive leadership team following the acquisition of the company by the carlyle group from johnson & johnson. in his first act as ortho's chairman and ceo, dr. martin d. madaus announced key appointments in finance, operations, legal and commercial to advance strategic sectors of the in vitro diagnostics (ivd) business.